Evidence map›Paper›PMID 25591850›Full record

ArticleColloids and surfaces. B, Biointerfaces2015

Multifunctional drug nanocarriers formed by cRGD-conjugated βCD-PAMAM-PEG for targeted cancer therapy.

Manju Saraswathy, Gavin T Knight, Srikanth Pilla, Randolph S Ashton, Shaoqin Gong

Open access · greenAbstract read
In one paragraph

Article in Colloids and surfaces. B, Biointerfaces, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 44 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Manju Saraswathy *Department of Biomedical Engineering and Wisconsin Institutes for Discovery, University of Wisconsin-Madison, Madison, WI 53706, USA.
Gavin T Knight *Department of Biomedical Engineering and Wisconsin Institutes for Discovery, University of Wisconsin-Madison, Madison, WI 53706, USA.
Srikanth PillaDepartment of Biomedical Engineering and Wisconsin Institutes for Discovery, University of Wisconsin-Madison, Madison, WI 53706, USA.
Randolph S AshtonDepartment of Biomedical Engineering and Wisconsin Institutes for Discovery, University of Wisconsin-Madison, Madison, WI 53706, USA.
Shaoqin GongDepartment of Biomedical Engineering and Wisconsin Institutes for Discovery, University of Wisconsin-Madison, Madison, WI 53706, USA.
University of Wisconsin–Madison · USWisconsin Institutes for Discovery · US

Funding

Targeted Therapy of Neuroendocrine Cancers Via the Notch Signaling PathwayK25CA166178 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI GONG, SHAOQIN - · 2013 to 2017
$994k
NCI NIH HHS 1K25CA166178NCI NIH HHS K25 CA166178
6 · The paper itself

Abstract

Polyamidoamine (PAMAM) dendrimer was conjugated with both carboxymethyl-β-cyclodextrin (βCD) and poly(ethylene glycol) (PEG). Cyclic RGD peptide, used as a tumor targeting ligand, was then selectively conjugated onto the distal ends of the PEG arms. The resulting βCD-PAMAM-PEG-cRGD polymer was able to form stable and uniform nanoparticles (NPs) in aqueous solution. Doxorubicin (Dox), a model hydrophobic anticancer drug, was effectively encapsulated in the NPs via an inclusion complex formed between the drug and βCD. The Dox loading level was 16.8 wt%. The cellular uptake of cRGD-conjugated Dox-loaded NPs in the U87MG cell line was much higher than that of non-targeted NPs. Furthermore, the anti-proliferative effect of the cRGD-conjugated NPs was superior to that of free drug and non-targeted NPs. These results suggest that NPs formed by βCD-PAMAM-PEG-cRGD with a high drug payload may significantly improve the anticancer efficacy by tumor-targeted delivery and enhanced cellular uptake.

Indexed as

Antineoplastic Agentsbeta-CyclodextrinsCell Line, TumorCell ProliferationDose-Response Relationship, DrugDoxorubicinDrug CarriersDrug Screening Assays, AntitumorHumansMolecular StructureNanostructuresPeptides, CyclicPolyaminesPolyethylene GlycolsStructure-Activity RelationshipAntineoplastic Agentsbeta-Cyclodextrinscyclic arginine-glycine-aspartic acid peptideDoxorubicinDrug CarriersPeptides, CyclicPoly(amidoamine)PolyaminesPolyethylene GlycolscRGDDrug loadingPAMAM dendrimerTargeted deliveryβ-Cyclodextrin

Identifiers

PMID25591850
PMCPMC4336634
OpenAlexW1970475276

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.